F-box only protein 31 (FBXO31), a subunit of the Skp1-Cul1-F box ubiquitin ligase, plays a crucial role in DNA damage response and tumorigenesis. Yet its expression and function vary in different types of human cancer. The expression of FBXO31 in esophageal squamous cell carcinoma (ESCC) and its association with clinicopathological features is not well studied. The underlying mechanism by which deregulated FBXO31 contributes to ESCC tumorigenesis is largely unknown. By immunohistochemical analysis of a tissue microarray containing 85 cases of ESCC and matched adjacent noncancerous tissue and an additional 10 cases of ESCC tissue samples, we found that FBXO31 was overexpressed in ESCC, and that its expression was significantly correlated with histological grade (p 5 0.04) and clinical stage (p 5 0.022). Higher expression of FBXO31 was associated with poor prognosis in univariate (p 5 0.013) and multivariate (p 5 0.014) analyses. We found that FBXO31 functioned as an antiapoptotic molecule in ESCC cells exposed to different types of genotoxic stress. Knockdown of FBXO31 inhibited serum-starved cell viability and decreased tumorigenicity of ESCC cells. In addition, the antiapoptotic effects of FBXO31 were associated with deactivation of stress-induced MAPK p38a and JNK. Furthermore, in vitro and in vivo data showed that silencing of FBXO31-sensitized ESCC cells and tumors to cisplatin treatment. Taken together, in addition to revealing that FBXO31 is an independent prognostic marker for ESCC, our findings substantiate a novel regulatory role of FBXO31 in tumorigenesis and drug resistance of ESCC.
FBXO31 is regarded as a candidate tumor suppressor gene in breast, 6 ovarian, 12 prostate, 13 hepatocellular 7 and gastric cancers 9 due to loss of heterozygosity at its gene locus and/or downregulation of gene expression. Yet interestingly, higher FBXO31 mRNA expression was found to be correlated with depth of tumor invasion, clinical stage and poor prognosis of patients with ESCC. 8 More recently, overexpression of FBXO31 was also observed in lung cancer in which higher expression of FBXO31 is significantly correlated to tumor size and infiltration, clinical stages and metastasis. 10 The functional role of FBXO31 in human cancer, therefore, remains controversial. It is thus imperative that the specific role of FBXO31 in each cancer type be defined and functionally validated to obtain a better understanding of its function, with the ultimate goal of exploiting it as a potential therapeutic target.
We previously observed that FBXO31 could downregulate p-p38 activation in ESCC cells in response to UV stress by mediating K48-linked ubiquitination and proteasome degradation of MKK6, 14 but whether the effect of FBXO31 on cell apoptosis was due to deregulation of p38 exclusively, and not that of other MAPKs such as JNK and ERKs, remain unknown. In this study, we have extended our efforts to demonstrate that FBXO31 functions as an antiapoptotic molecule by interfering with activation of both p38a and JNK upon stresses. Our results showed that this mechanism could favor the survival of ESCC cells in stringent environment and confer resistance to chemotherapy.
Material and methods

Tissue microarray and immunohistochemistry
A commercially available paraffin-embedded human esophageal tissue array was bought from Shanghai Outdo Biotech, Shanghai, China (catalog no. HEso-Squ180Sur-01). Demographic and clinicopathological data including clinical staging (according to the American Joint Committee on Cancer staging system) and survival data were provided by the manufacturer. Tissue sections were deparaffinized, soaked in 0.01 M sodium citrate buffer and boiled in a microwave oven for 5 min at 500 W to retrieve cell antigens. After treatment with 3% hydrogen peroxide to inactivate endogenous peroxidase and blocking with normal goat serum to reduce nonspecific staining, the sections were incubated with anti-FBXO31 antibody (ab86137; Abcam, Cambridge, UK) at a dilution of 1:100 overnight at 48C. Tissue sections were immunohistochemically stained using Envision reagents (Envision 1 Dual link/HRP; Dako, Denmark). All sections were counterstained with hematoxylin. The results were scored as described by Shimizu et al. 15 The distribution of positive cells was scored as follows: none (not stained; score 0), focal (less than one-third of cells stained; score 1), multifocal (less than two-thirds of cells stained; score 2) and diffuse (most cells stained; score 3). The intensity of staining was scored as follows: none (not stained; score 0), mild (score 1) and strong (clearly identified under 403 magnification; score 2). Two experienced pathologists blinded to the clinicopathologic information of the patients independently evaluated immunostaining scores. The cases for which there was disagreement were revaluated jointly for consensus. For each case, the final immunohistochemical (IHC) score for FBXO31 immunostaining was calculated by adding the scores of distribution and intensity to give a final score: 0 5 (2), 2 5 (6). 3 5 (1), 4 5 (1 1), 5 5 (1 1 1) . A final score of 3 was considered low expression and 4 was considered high expression. The specificity of the primary antibody was validated using paraformaldehyde-fixed, paraffin-embedded ESCC cells with ectopic FBXO31 expression and ESCC cells with knockdown as positive and negative controls, respectively. Isotype control antibody (Abcam ab37415) applied on ESCC tissue sections (obtained with informed consent and institutional approval from patients at the Second Xiangya Hospital of Central South University) at the same dilution as the primary antibody served as additional negative control.
Cell culture and establishment of stable cell lines ESCC cell lines KYSE150, KYSE510 and KYSE30 16 obtained from DSMZ (Braunschweig, Germany) were cultured in RPMI 1640 (Sigma, St. Louis, MO, USA) containing 10% fetal bovine serum (FBS) (Invitrogen, Gaithersburg, MD, USA). KYSE150 and KYSE510 were used to construct stable FBXO31-knockdown cell lines, while KYSE30 with relatively low endogenous FBXO31 expression was used for stable overexpression study.
Plasmids and siRNA
Details of FBXO31-expression plasmid and the two shRNA sequences used for FBXO31-knockdown were reported previously. 14 
Exposure of cells to genotoxic stresses
Serum starvation: cells under serum starvation were cultured in RPMI 1640 containing 0.25% FBS for 48-72 hr. Hypoxia:
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hypoxic cell cultures were performed in an Invivo2400 hypoxia workstation (Ruskin Technology, Leeds, UK) at 1% O 2 , 5% CO 2 , 378C. UV treatment: cells were serum starved for 16 hr, then the medium was removed and the cells were irradiated with UV at 50 J/m 2 using an UV-crosslinker (Spectroline, NY, USA). After irradiation, cells were fed with serumfree medium and cultured at 378C. Ionizing radiation (IR): cells were cultured in 35 mm dish for 24 hr and then subjected to g-irradiation from a 137Cs source using a Gammacell 3000 Elan machine (MDS Nordion, Ottawa, ON, Canada). Cisplatin (DDP) treatment: cells were exposed to freshly prepared culture medium containing 40 lM DDP (Merck, Darmstadt, Germany) in the absence or presence of 3 lM JNK inhibitor SP600125 (TargetMol, MA, USA) or 10 lM p38 inhibitor SB203580 (TargetMol) for indicated durations.
Immunoblotting and antibodies
Preparation of whole-cell lysates and immunoblotting were performed as described previously. 17 Anti-FBXO31 antibody (ab86137) was purchased from Abcam, Cambridge, UK and MAP Kinase Activation Sampler Kit (#612544) including phospho-specific antibodies of ERK 1/2, p38a and JNK 1/2 and total ERK1, p38a and JNK were purchased from BD Biosciences (San Diego, CA, USA). Pan-PARP and cleaved caspase 3 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay Cell viability was measured using MTT proliferation assay. Briefly, about 1,000 cells were seeded in 96-well plates and cultured for 24 hr. Cell viability was examined at the indicated time points. The optical density (OD) was measured at a wavelength of 570 nm on a Labsystem multiskan microplate reader (Merck Eurolab, Dietikon, Switzerland). Each data point represented the mean and standard deviation (SD) of three independent experiments.
Apoptosis detection
Cells treated with indicated genotoxic stresses and untreated control cells were stained using the Annexin V-FITC Apoptosis Detection Kit (Sigma), which includes propidium iodide (PI) to label cellular DNA in cells with compromised cell membrane. Then the population of early apoptotic cells, late apoptotic and/or necrotic cells and viable cells were analyzed by flow cytometry. The mean values and standard deviations were calculated from three independent experiments.
Soft agar assays
Soft agar assay was performed as described previously. 18 Briefly, 5 3 10 4 cells were plated in RPMI 1640 containing 0.33% agar and 10% FBS, on top of a 0.6% agar layer with 10% FBS in RPMI 1640 medium. After 2 weeks, all colonies were counted under the microscope.
Animal xenografts
All the animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong. The stable cell lines KYSE150-scrambled-shRNA and KYSE150-FBXO31-shRNA#1 were suspended in 50% Matrigel (BD Biosciences) and injected subcutaneously into the right and left flank of athymic nude mice respectively (n 5 6). Tumor volume was quantified using the equation V 5 (length 3 width 2 )/2. For drug treatment experiments, nude mice were randomly divided into two groups (n 5 6/group) one week after implantation of tumor xenografts (when the tumor reached 5 mm diameter), and given intraperitoneal injection of either vehicle (dimethyl sulfoxide in PBS) or cisplatin (2 mg/kg) (Merck, Darmstadt, Germany) at 4-day intervals for 3 weeks. All animals were euthanized at the end of the experiments.
Proteomic evaluation of FBXO31 complexes
The binding proteins of FBXO31 were identified by coimmunoprecipitation followed by mass spectrometry. HeLa cells transfected with pFGFPC2-FLAG-FBXO31 plasmid or control vector were treated with MG132 for 4 hr. Cell lysates were harvested and then immunoprecipitated with anti-FLAG M2 antibody (Sigma) at 48C overnight and incubated with Protein A/G Magnetic Beads (Thermo Scientific, Gaithersburg, MD, USA) for 1 hr at room temperature. The FBXO31 binding complexes were cut from SDS-PAGE and analyzed by reverse-phase nanospray liquid chromatography-tandem mass spectrometry. The spectra from tandem mass spectrometry were used for searching against the nonredundant International Protein Index human protein database (version 201405) with the Bioworks browser (rev.3.1).
Statistical analysis
The results were analyzed using SPSS (Chicago, IL, USA). The data were expressed as the mean 6 SD and compared by ANOVA unless stated otherwise. FBXO31 expression between tumor tissues and matched nontumor tissues was analyzed with the paired Student's t test. The association between FBXO31 expression and various clinicopathological parameters was evaluated with the v 2 test. The Cox proportional hazard regression model was used for univariate and multivariate analyses to determine the effects of the clinicopathological variables and FBXO31 expression on the patient survival. Only variables with p values <0.05 in univariate analysis were included in multivariate analysis. Survival curves were calculated using the Kaplan-Meier method using log-rank test. All statistical tests were two-sided, and p values <0.05 were deemed statistically significant.
Results
FBXO31 overexpression in ESCC specimens was positively correlated with histological grade, clinical stage and postoperative survival in patients with ESCC
Immunohistochemical staining was performed on a tissue microarray containing 180 cores/spots, of which 170 were paired ESCC tissue and corresponding adjacent nonneoplastic mucosa tissue from 85 patients, and the remaining spots were ESCC tissue from 10 other patients (Fig. 1a) . The paired ESCC and matching non-neoplastic esophageal tissue in the array were compared for FBXO31 expression. Among the 85 pairs, 9 pairs were excluded due to lack of either detectable tumor cells or normal epithelial cells, so that a total of 76 pairs were enrolled for comparison. As illustrated in Figure 1b which shows two pairs of ESCC and nonneoplastic esophageal tissue, the FBXO31 protein was detected in both the cytoplasm and nucleus (but mostly in the cytoplasm) of non-neoplastic esophageal epithelial cells, whereas it was localized in the cytoplasm of ESCC tumor cells. The specificity of the primary antibody for detecting FBXO31 in ESCC tissues, and in ESCC cell lines, was confirmed as shown in Supporting Information, Fig. 1 . As FBXO31 is an adaptor of SCF E3 ligase and reports so far indicate that its function is to mediate proteasomal degradation of cytoplasmic substrates, FBXO31 cytoplasmic staining was evaluated in this study. Our results showed that FBXO31 staining was weak in most of the non-neoplastic esophageal epithelial tissues (62 of 76) although some specimens showed a strong staining in the basal and suprabasal layers, with a gradual decrease in staining from the basal layer to the superficial layer (Fig. 1b) . In contrast, 68.4% (52 of 76) of the cases of ESCC showed strong cytoplasmic FBXO31 staining, with a significantly higher mean score compared with paired noncancerous tissues (p < 0.001, n 5 76) (Fig. 1c) . Examples of ESCC specimens with strong positive (111) and negative (2) cytoplasmic FBXO31 staining are given in Figure 1d . The correlations between the clinicopathological parameters and the expression of FBXO31 in all the informative ESCC cases (total 93 cases) were analyzed. The data showed that the expression level of FBXO31 was significantly associated with histological grade and clinical stage, but not with age, gender, tumor location, tumor size, lymph node metastasis (N stage) and depth of tumor infiltration (T stage) ( Table 1) . Univariate Cox regression analyses indicated that FBXO31 expression, and gender, tumor size, lymph node metastasis and clinical stage were significantly associated with patient survival (Table  2) . Furthermore, a multivariate Cox regression analysis further confirmed FBXO31 expression and tumor size as independent predictors of shorter overall survival (Table 2) . Kaplan-Meier analysis showed that patients with high FBXO31 expression had significantly shorter overall survival (median 5 15 months) compared with patients with low FBXO31 expression (median 5 37.5 months; p 5 0.0123, log-rank test, Fig. 1e ).
FBXO31 suppressed stress-induced cell apoptosis, inhibited serum-starved cell proliferation and decreased tumorigenicity of ESCC cells As FBXO31 expression was found to be upregulated in ESCC and correlated with clinical stage and poor prognosis, we next determined whether FBXO31 plays an oncogenic role in ESCC. As our previous study showed that FBXO31 can suppress cell apoptosis induced by UV exposure, 14 and it is widely accepted that tumor cells grow in a very stringent environment due to oxygen, nutrient and energy deprivation, 19 we investigated the biological effects of FBXO31 in ESCC cells exposed to various environmental stresses. We found that knockdown of FBXO31 using two different shRNAs designated shRNA#1 and shRNA#2 enhanced apoptosis of KYSE150 cells under serum starvation, hypoxia and IR treatment conditions, as indicated by increased expressions of cleaved caspase 3 and PARP (poly ADP-ribose polymerase) (Fig. 2a) . Annexin V staining confirmed that knockdown of FBXO31 increased cell apoptosis upon hypoxia treatment (Fig. 2b) . Furthermore, we found that FBXO31-knockdown led to a significant reduction in proliferation of ESCC cells cultured under serum-starved condition but not under serum-containing condition (Fig. 2c) , suggesting that FBXO31 may favor the survival of ESCC cells in stringent environment. Consistently, in vitro and in vivo experiments showed that FBXO31 decreased tumorigenicity of ESCC cells, as evidenced by the decreased ability of KYSE150 cells with FBXO31 knockdown to form colonies in soft agar (Fig. 2d) and to develop tumors in nude mice (Fig.  2e) , compared with KYSE150 cells expressing scrambled shRNA. Taken together, these results support an oncogenic role for FBXO31 in ESCC.
Suppression of cell apoptosis by FBXO31 was associated with deactivation of stress-induced MAPK p38a and JNK
We previously reported that FBXO31 could suppress sustained p38 activation upon genotoxic damage.
14 To determine whether the suppressive effect of FBXO31 on cell apoptosis involves multiple MAPK pathways, stable cancer cell lines with FBXO31-knockdown were compared with corresponding control cells expressing scrambled shRNA for expression of activated forms of p38, JNK and ERK. The results showed that, in addition to upregulating p-p38, knockdown of FBXO31 in KYSE510 and KYSE150 cells increased p-JNK1/2 but not p-ERK expressions in both cell lines (Fig. 3a) , indicating that FBXO31 may regulate specific stress-activated MAPKs. On the other hand, gain-of-function study showed that stable FBXO31 overexpression in KYSE30 cells suppressed JNK1/2 phosphorylation upon UV irradiation (Fig. 3b) , and confirmed our previous finding that FBXO31 negatively regulates p38 activation. 14 Furthermore, stable FBXO31-knockdown enhanced phosphorylation of both p38a and JNK1/2 compared to the cells expressing scrambled shRNA, and the effect was sustained up to 12 hr after UV exposure; consequently, higher expressions of cleaved caspase 3 and PARP were found in ESCC cell lines expressing FBXO31 shRNA#1 (Fig. 3c) .
FBXO31 promoted cisplatin chemoresistance in ESCC
Cisplatin (DDP) is a commonly used first-line chemotherapeutic drug for ESCC, and previous studies have established that DDP can initiate cancer cell apoptosis through the activation of stress-activated MAPKs. 20 Whether deregulation of FBXO31 could affect the sensitivity of ESCC cell lines to DDP treatment was investigated. In vitro experiments showed that stable knockdown of FBXO31 in KYSE150 cells sensitized the ESCC cells to DDP treatment, as evidenced by increased expression of phosphorylated MAPKs and cleaved caspase 3 and PARP (Fig. 4a) , and increase in early-and late-apoptotic cell populations (Fig. 4b) . Then we used p38 and JNK inhibitors to determine whether FBXO31-mediated chemoresistance depends on p38 and/or JNK activity. Annexin V staining (Fig. 4b ) and western blotting (Fig. 4c ) results showed that inhibition of either p38 or JNK pathway could reverse the effect of FBXO31-knockdown on cell apoptosis upon cisplatin treatment, indicating that both pathways are indispensable for FBXO31 to exert anti-apoptotic effects. Importantly, in vivo experiment showed that ESCC tumor xenografts with FBXO31 knockdown were significantly more responsive to DDP treatment than tumors expressing scrambled shRNAs (Fig. 4d) . 
FBXO31-binding proteins identified using mass spectrometry
To provide mechanistic insight on how FBXO31 regulates JNK and cell apoptosis, mass spectrometry was used to analyze the binding proteins of FBXO31. The spectra of three potential binding proteins-argininosuccinate synthetase (ASS1), acetyl-CoA acetyltransferase and mitochondrial 2-oxoglutarate/malate carrier protein-are shown in Supporting Information, Fig. 2 .
Discussion
Deregulation of F-box proteins has been shown to play critical roles in cancer development, progression and metastasis. 2 Given that F-box proteins are frequently deregulated in human cancer and the key roles they play in regulating various aspects of the tumorigenic phenotype, F-box proteins represent attractive molecular targets for therapeutic intervention. For example, pharmacological inactivation of Skp2 SCF ubiquitin ligase was recently reported to restrict cancer stem cell traits and cancer progression. 21 Yet due to multiple substrates recognized by F-box proteins and specific role of the substrates in different cells and tissues, a careful examination of the biochemical activities of F-box proteins according to tissue context is important if these proteins are to be exploited as intervention targets. FBXO31 is an important DNA damage responsive protein and cell cycle regulator. 5, 6, 11, 14 FBXO31 expression was reported to be downregulated in several different types of cancers 6, 7, 9 and is therefore regarded as a candidate tumor suppressor. The tumor-suppressive function of FBXO31 may be attributed to its ability to mediate ubiquitination and proteolysis of oncogenic substrates such as cyclin D1, 5 CDT1
22 and MDM2. 11 However, studies on the role of FBXO4, FBXO31, Skp2 and FBXW8 in regulating the stability of cyclin D1 suggest that FBXO31 mediates cyclin D1 degradation in a cell type-specific manner. 23 With respect to CDT1, it was reported that the ability of FBXO31 to degrade CDT1 in the G2 phase of cell cycle is limited and may be required to dampen the level of CDT1 rather than obliterate its activity. 2 Therefore, the individual contribution of cyclin D1, CDT1 and MDM2 to the tumor suppressor functions of FBXO31 in specific tissue context merits further investigation.
Relatively little is known about FBXO31 functioning as an oncogene. Thus far, overexpression of FBXO31 has only been reported in lung cancer 10 and ESCC. 8 In the latter study, Kogo et al. determined FBXO31 mRNA expression in ESCC of 68 patients using quantitative RT-PCR analysis and found that higher expression of FBXO31 was associated with tumor invasion depth, clinical stage and poor prognosis. 8 They also found a significant association between cyclin D1 amplification and elevated FBXO31 expression, 8 but whether FBXO31 overexpression can accelerate the degradation of cyclin D1 in ESCC (as proposed by the authors), and the underlying mechanism by which FBXO31 exerts oncogenic function had not been elucidated. In this study, we found that FBXO31 is overexpressed at the protein level in ESCC and that immunohistochemical expression of FBXO31 has prognostic significance. More importantly, the results of this study, together with that of our earlier study which showed that FBXO31 interferes with p38 activation, 14 substantiate that FBXO31 functions as an antiapoptosis molecule by suppressing activation of MAPK pathways upon genotoxic stresses, thereby favoring the survival of ESCC cells under stringent conditions. These findings therefore underpin an oncogenic role for FBXO31 in ESCC. The reason why FBXO31 is overexpressed in ESCC remains to be explored. A recent review provided valuable insight into how the expression of F-box proteins may be suppressed at the post-transcriptional level by microRNAs. 24 As relatively is known about miRNAs that can target oncogenic F-Box proteins to exert tumor suppressive effects, identifying miRNAs that regulate FBXO31 will shed light on this important mechanism.
As FBXO31 does not interact with MKK4 14 and MKK7 (data not shown), it is unlikely that FBXO31 can affect JNK activation by directly mediating the degradation of these upstream kinases of JNK. Our preliminary results from mass spectrometry indicated that argininosuccinate synthetase (ASS1)-an enzyme that catalyzes the synthesis of argininosuccinate from citrulline and aspartate-is an FBXO31-interacting protein ( Supporting Information, Fig. 2 ). According to Lu et al., 25 partial deletion of ASS1 decreases LPSinduced cell apoptosis in liver through decreased phosphorylation of JNK and increased MAPK phosphatase-1 (which can deactivate JNK signaling). Furthermore, loss of ASS1 expression has been reported in several types of cancer including hepatocellular carcinoma, melanoma, mesothelioma, renal cell carcinoma and prostate cancer. 26 Here, we showed that FBXO31 is highly expressed in ESCC and that it deregulates p38a-and JNK-mediated apoptosis. Whether FBXO31 deregulates JNK by targeting ASS1 for degradation, and whether this mechanism protects ESCC cells from apoptosis, or promotes tumor development and chemoresistance are new dimensions that warrant detailed investigation. In addition to ASS1, the mass spectrometry analysis also showed that FBXO31 could bind to mitochondrial proteins such as acetyl-CoA acetyltransferase and mitochondrial 2-oxoglutarate/malate carrier protein (Supporting Information, Fig. 2 ). Whether FBXO31 affects stress-induced apoptosis and JNK pathway through binding to those proteins also merit further elucidation. Apoptosis plays an essential role in maintaining cellular homeostasis, and its deregulation can contribute to tumor progression, poor clinical outcome and drug resistance. 27 Our results showed that FBXO31 exerted antiapoptotic effect in ESCC cell lines by inhibiting p38a and JNK activation (Figs.  2a and 3c) . The antiapoptotic role of FBXO31 is consistent with our finding of high FBXO31 expression in ESCC and its association with poor prognosis (Fig. 1 and Tables 1 and 2 ). The results in Figure 2 showed that FBXO31 functions as oncogenic protein by increasing the tumorigenic potential of ESCC cells in vitro and in vivo. We speculate that whether FBXO31 plays an oncogenic or a tumor suppressive role in other malignancies may depend on the role of p38 and JNK in specific cancer types. Both p38 and JNK can exert proapoptotic and antiapoptotic effects depending on cell type, nature and duration of the stimuli. 28, 29 Moreover, many other types of human cancer have altered expression or activity of JNK and p38 MAPK components to facilitate cell proliferation, survival and invasion. 29 It is therefore possible that FBXO31 is downregulated in tumors that require p38 or JNK activation for proliferation or survival. As a negative regulator of MAPK, the low expression level of FBXO31 in breast cancer may indirectly explain the poor outcome associated with p38 activation in patients with lymph node-positive breast carcinoma. 30 Hence, discrepancy in FBXO31 expression among different cancer types may be due to different adaptations of cancer cells to gain growth/survival advantage in stringent environments.
As FBXO31 suppressed apoptosis of ESCC cells, whether FBXO31 could affect chemosensitivity of cancer cells was also investigated in this study. The data showed that knockdown of FBXO31 sensitized ESCC cells to DDP treatment (Fig. 4) , which substantiates that FBXO31 may have a role in drug resistance. Many chemotherapeutic drugs require a functional p38a and JNK pathway for efficient induction of cell apoptosis. 31 Phosphatases that dephosphorylate and deactivate p38 and JNK signaling have been found to be significant mediators for chemoresistance, 32 and inhibiting phosphatases that negatively regulate MAPK signaling had been suggested to be a strategy worth exploring for sensitizing cancer cells to apoptotic death. 29 In the same context, targeting of FBXO31 can be exploited to induce p38 and/or JNK activation to help cancer cells overcome chemoresistance.
In conclusion, we found that FBXO31 protects ESCC cells from apoptosis by inhibiting p38 and JNK activation, and that knockdown of FBXO31 sensitized the ESCC cells to DDP treatment. Effective therapy targeting the FBXO31-MAPK pathway may help control ESCC progression and increase chemosensitivity.
